TrialBMC oral health2026

Efficacy and safety of schedule-modified oral capecitabine/S-1 as maintenance therapy for stage N3 nasopharyngeal carcinoma after definitive chemoradiotherapy: a multicentre, single-arm phase II clinical trial.

Xiang Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.